


Supplementary Table 1: Induction regimens received upon diagnosis of pPCL


| INDUCTION REGIMENS | N (%) |
|-------------------------------------------------|--------------|
| PI alone | 24 (35%) |
| • CyBord | 16 |
| • CyKd | 1 |
| • VMP | 1 |
| • PAD | 1 |
| • VDoxD | 1 |
| • Vd | 3 |
| • VD-PACE | 1 |
| IMiD alone | 4 (6%) |
| • CyRd | 1 |
| • Rd | 1 |
| • Td | 2 |
| PI and IMiD combination | 38 (56%) |
| • VRd | 21 |
| • VTd | 3 |
| • KRd | 3 |
| • VDT-PACE or VDR-PACE | 11 |
| Monoclonal antibody/ PI/IMiD combination | 2 (3%) |
| • Dara-IRd | 1 |
| • Elo-VRd | 1 |

Supplementary Table 2: IMWG-based best hematological responses observed during first line therapy

| Induction regimens (N) | ORR % | ≥VGPR% | CR% | VGPR % | PR% | SD% | PD% |
|---------------------------------|--------------|---------------|------------|---------------|------------|------------|------------|
| All regimens (57) | 51 (90%) | 45 (79%) | 27 (47%) | 18 (32%) | 6 (11%) | 3 (5%) | 3 (5%) |
| • PI or IMiD alone (12) | 10 (83%) | 8 (67%) | 2 (17%) | 6 (50%) | 2 (17%) | – | 2 (16%) |
| • PI or IMiD + ASCT (12) | 11 (92%) | 11 (92%) | 7 (58%) | 4 (34%) | – | 1 (8%) | – |
| • PI-IMiD alone (10) | 8 (80%) | 5 (50%) | 4 (40%) | 1 (10%) | 3 (30%) | 1 (10%) | 1 (10%) |
| • PI-IMiD + ASCT (20) | 19 (95%) | 18 (90%) | 12 (60%) | 6 (30%) | 1 (5%) | 1 (5%) | – |
| • PI-IMiD + Allo-SCT (3) | 3 (100%) | 3 (100%) | 2 (67%) | 1 (33%) | – | – | – |



Supplementary Figure 1A



Supplementary Figure 1B